Targeting B-cell acute lymphoblastic leukemia with combined therapies
Combinatorial targeting for the treatment of B-cell acute lymphoblastic leukemia
This study is looking at new ways to treat a tough type of leukemia called B-cell acute lymphoblastic leukemia, especially for those with the Philadelphia chromosome, by combining two treatments to help stop the cancer cells from growing and finding a better way to deliver these treatments directly to the cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | West Virginia University NIH-funded |
| Lab location | 1 site (Morgantown, United States) |
| Project ID | NIH-10986073 on NIH RePORTER |
What this research studies
This research focuses on improving treatment for B-cell acute lymphoblastic leukemia (B-ALL), particularly the challenging Philadelphia chromosome subgroup. It aims to combine two therapeutic approaches: using STAT5 siRNA to inhibit the growth of leukemia cells and a small molecule called NL-1 that has shown anti-leukemic effects. The study will also develop a delivery system to effectively transport these treatments to the cancer cells. By targeting both pathways simultaneously, the researchers hope to enhance the effectiveness of the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with B-cell acute lymphoblastic leukemia, especially those with the Philadelphia chromosome mutation.
Not a fit: Patients with other types of leukemia or those who do not have B-cell acute lymphoblastic leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with high-risk B-cell acute lymphoblastic leukemia, potentially improving survival rates.
How similar studies have performed: There is mounting evidence suggesting that targeting STATS signaling has shown promise in treating high-risk B-cell ALL, indicating that this approach may build on previous successes.
Where this research is happening
Morgantown, United States
- West Virginia University — Morgantown, United States (Active)
Researchers
- Principal investigator: Bobbala, Sharan Kumar Reddy — West Virginia University
- Study coordinator: Bobbala, Sharan Kumar Reddy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.